• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

迟发性多发性硬化症与达到残疾里程碑的速度加快有关。

Late-onset MS is associated with an increased rate of reaching disability milestones.

机构信息

Department of Neurology, Danish Multiple Sclerosis Center, Rigshospitalet Glostrup, Valdemar Hansens Vej 2, indgang 8, 2. sal, 2600, Glostrup, Denmark.

出版信息

J Neurol. 2021 Sep;268(9):3352-3360. doi: 10.1007/s00415-021-10490-0. Epub 2021 Mar 7.

DOI:10.1007/s00415-021-10490-0
PMID:33677675
Abstract

OBJECTIVE

To describe patient characteristics and assess the risk of disability worsening in patients of different age groups with focus on late-onset multiple sclerosis (LOMS) defined as disease onset after the age of 50 years.

METHODS

The nationwide population-based Danish Multiple Sclerosis Registry served as data source. We described baseline characteristics and analyzed rates of reaching Expanded Disability Status Scale (EDSS) milestones.

RESULTS

We identified 28,232 patients with MS with a known year of clinical onset, of which 2661 had LOMS. The LOMS group had a higher proportion of males and patients with primary progressive disease course, and they were less likely to receive disease-modifying therapy. The initial rate of reaching EDSS milestone 6 after diagnosis was higher in LOMS [hazard ratio (HR) 1.53; 95% confidence interval (CI) 1.14-2.06]; however, when assessing the risk of reaching EDSS 6 according to age, the HR was significantly lower for the LOMS group (HR 0.307; 95% CI 0.221-0.426).

CONCLUSION

The clinical characteristics and treatment approaches for patients with LOMS differ from their younger counterparts. Following diagnosis, patients with LOMS initially have an increased rate of reaching EDSS score 6; however, the risk of reaching EDSS score 6 at any given age is higher in patients with non-LOMS.

摘要

目的

描述不同年龄组患者的特征,并评估其残疾恶化风险,重点关注发病年龄在 50 岁及以后的晚发型多发性硬化症(LOMS)。

方法

本研究以全国范围内基于人群的丹麦多发性硬化症注册处为数据源。我们描述了基线特征,并分析了达到扩展残疾状态量表(EDSS)里程碑的比率。

结果

我们确定了 28232 名具有已知临床发病年份的 MS 患者,其中 2661 名患有 LOMS。LOMS 组中男性和原发性进行性疾病病程患者的比例较高,且更不可能接受疾病修正治疗。诊断后达到 EDSS 里程碑 6 的初始速率在 LOMS 组中更高[风险比(HR)1.53;95%置信区间(CI)1.14-2.06];然而,当根据年龄评估达到 EDSS 6 的风险时,LOMS 组的 HR 显著降低(HR 0.307;95% CI 0.221-0.426)。

结论

LOMS 患者的临床特征和治疗方法与年轻患者不同。诊断后,LOMS 患者最初达到 EDSS 评分 6 的比率增加;然而,在任何给定年龄达到 EDSS 评分 6 的风险在非 LOMS 患者中更高。

相似文献

1
Late-onset MS is associated with an increased rate of reaching disability milestones.迟发性多发性硬化症与达到残疾里程碑的速度加快有关。
J Neurol. 2021 Sep;268(9):3352-3360. doi: 10.1007/s00415-021-10490-0. Epub 2021 Mar 7.
2
Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.迟发性多发性硬化的临床特征和长期预后:一项瑞典全国性研究。
Neurology. 2024 Mar 26;102(6):e208051. doi: 10.1212/WNL.0000000000208051. Epub 2024 Feb 23.
3
Is late-onset multiple sclerosis associated with a worse outcome?迟发性多发性硬化症是否与更差的预后相关?
Neurology. 2006 Sep 26;67(6):954-9. doi: 10.1212/01.wnl.0000237475.01655.9d.
4
Older Age at Multiple Sclerosis Onset Is an Independent Factor of Poor Prognosis: A Population-Based Cohort Study.多发性硬化症发病年龄较大是预后不良的独立因素:一项基于人群的队列研究。
Neuroepidemiology. 2017;48(3-4):179-187. doi: 10.1159/000479516. Epub 2017 Aug 10.
5
Comparative analysis of cognitive and physical characteristics in late-onset, adult-onset and early-onset multiple sclerosis patients.迟发性、成人发病型和早发性多发性硬化症患者认知和身体特征的比较分析。
Mult Scler Relat Disord. 2024 Oct;90:105810. doi: 10.1016/j.msard.2024.105810. Epub 2024 Aug 6.
6
Is Time to Reach EDSS 6.0 Faster in Patients with Late-Onset versus Young-Onset Multiple Sclerosis?晚发型与早发型多发性硬化症患者达到扩展残疾状态量表(EDSS)6.0的时间更快吗?
PLoS One. 2016 Nov 1;11(11):e0165846. doi: 10.1371/journal.pone.0165846. eCollection 2016.
7
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis.儿童发病多发性硬化症患者持续性残疾的风险。
JAMA Neurol. 2021 Jun 1;78(6):726-735. doi: 10.1001/jamaneurol.2021.1008.
8
Late-onset multiple sclerosis: disability trajectories in relapsing-remitting patients of the Italian MS Registry.迟发性多发性硬化症:意大利多发性硬化症注册研究中复发缓解型患者的残疾轨迹。
J Neurol. 2024 Apr;271(4):1630-1637. doi: 10.1007/s00415-023-12152-9. Epub 2024 Jan 3.
9
Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.儿童发病多发性硬化症患者延迟治疗对残疾的长期影响:一项前瞻性丹麦队列研究。
Mult Scler Relat Disord. 2020 May;40:101956. doi: 10.1016/j.msard.2020.101956. Epub 2020 Jan 17.
10
Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis.在儿童、成人和晚发性多发性硬化症中,与复发活动状态无关的残疾进展轨迹有所不同。
J Neurol. 2024 Oct;271(10):6782-6790. doi: 10.1007/s00415-024-12638-0. Epub 2024 Aug 23.

引用本文的文献

1
Response to therapy in a cohort of patients with late-onset multiple sclerosis.一组迟发性多发性硬化症患者的治疗反应
Mult Scler J Exp Transl Clin. 2025 Jul 29;11(3):20552173251360357. doi: 10.1177/20552173251360357. eCollection 2025 Jul-Sep.
2
Multiple Sclerosis After the Age of 50 Years: A Comparative Analysis of Late Onset and Adult Onset.50岁之后的多发性硬化症:迟发性与成人发病型的比较分析
J Clin Neurol. 2025 May;21(3):201-212. doi: 10.3988/jcn.2024.0302.
3
Incidence of late onset multiple sclerosis in Italy: a population-based study.

本文引用的文献

1
The Danish Multiple Sclerosis Registry.丹麦多发性硬化症注册中心。
Brain Behav. 2021 Jan;11(1):e01921. doi: 10.1002/brb3.1921. Epub 2020 Oct 30.
2
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis.疾病修正药物可降低复发型多发性硬化的残疾进展。
Brain. 2020 Oct 1;143(10):3013-3024. doi: 10.1093/brain/awaa251.
3
Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study.迟发性和早发性复发缓解型多发性硬化症:来自回顾性长期随访研究的证据。
意大利迟发性多发性硬化症的发病率:一项基于人群的研究。
Sci Rep. 2024 Nov 28;14(1):29649. doi: 10.1038/s41598-024-81284-3.
4
De-escalation and Discontinuation of Disease-Modifying Therapies in Multiple Sclerosis.多发性硬化症中疾病修正疗法的降级和停药。
Curr Neurol Neurosci Rep. 2024 Sep;24(9):341-353. doi: 10.1007/s11910-024-01355-w. Epub 2024 Jul 12.
5
Management of multiple sclerosis in older adults: review of current evidence and future perspectives.老年人多发性硬化症的管理:当前证据的回顾与未来展望。
J Neurol. 2024 Jul;271(7):3794-3805. doi: 10.1007/s00415-024-12384-3. Epub 2024 Apr 30.
6
Challenges in Diagnosis and Therapeutic Strategies in Late-Onset Multiple Sclerosis.迟发性多发性硬化症的诊断挑战与治疗策略
J Pers Med. 2024 Apr 10;14(4):400. doi: 10.3390/jpm14040400.
7
Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.迟发性多发性硬化的临床特征和长期预后:一项瑞典全国性研究。
Neurology. 2024 Mar 26;102(6):e208051. doi: 10.1212/WNL.0000000000208051. Epub 2024 Feb 23.
8
Immunosenescence and multiple sclerosis: inflammaging for prognosis and therapeutic consideration.免疫衰老与多发性硬化症:炎症衰老对预后及治疗的考量
Front Aging. 2023 Oct 13;4:1234572. doi: 10.3389/fragi.2023.1234572. eCollection 2023.
9
Aging in multiple sclerosis: from childhood to old age, etiopathogenesis, and unmet needs: a narrative review.多发性硬化症中的衰老:从儿童期到老年期、病因发病机制及未满足的需求:一项叙述性综述
Front Neurol. 2023 Jun 2;14:1207617. doi: 10.3389/fneur.2023.1207617. eCollection 2023.
10
First-line therapies in late-onset multiple sclerosis: An Italian registry study.晚发性多发性硬化症的一线治疗:一项意大利登记研究。
Eur J Neurol. 2021 Dec;28(12):4117-4123. doi: 10.1111/ene.15006. Epub 2021 Jul 30.
Eur J Neurol. 2018 Dec;25(12):1425-1431. doi: 10.1111/ene.13745. Epub 2018 Aug 3.
4
Incidence of MS has increased markedly over six decades in Denmark particularly with late onset and in women.多发性硬化症的发病率在丹麦六十年间显著上升,尤其是在女性和发病较晚的人群中。
Neurology. 2018 May 29;90(22):e1954-e1963. doi: 10.1212/WNL.0000000000005612. Epub 2018 May 2.
5
Older Age at Multiple Sclerosis Onset Is an Independent Factor of Poor Prognosis: A Population-Based Cohort Study.多发性硬化症发病年龄较大是预后不良的独立因素:一项基于人群的队列研究。
Neuroepidemiology. 2017;48(3-4):179-187. doi: 10.1159/000479516. Epub 2017 Aug 10.
6
Excess mortality among patients with multiple sclerosis in Denmark has dropped significantly over the past six decades: a population based study.丹麦多发性硬化症患者的超额死亡率在过去六十年中显著下降:一项基于人群的研究。
J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):626-631. doi: 10.1136/jnnp-2017-315907.
7
Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study.多发性硬化症的生存率和死因:一项60年的纵向人群研究。
J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):621-625. doi: 10.1136/jnnp-2016-315238. Epub 2017 Apr 1.
8
Treatment decisions in multiple sclerosis - insights from real-world observational studies.多发性硬化症的治疗决策——来自真实世界观察性研究的见解。
Nat Rev Neurol. 2017 Feb;13(2):105-118. doi: 10.1038/nrneurol.2016.188. Epub 2017 Jan 13.
9
Is Time to Reach EDSS 6.0 Faster in Patients with Late-Onset versus Young-Onset Multiple Sclerosis?晚发型与早发型多发性硬化症患者达到扩展残疾状态量表(EDSS)6.0的时间更快吗?
PLoS One. 2016 Nov 1;11(11):e0165846. doi: 10.1371/journal.pone.0165846. eCollection 2016.
10
Increasing age at disability milestones among MS patients in the MSBase Registry.多发性硬化症患者在 MSBase 注册中心达到残疾里程碑的年龄不断增加。
J Neurol Sci. 2012 Jul 15;318(1-2):94-9. doi: 10.1016/j.jns.2012.03.017. Epub 2012 Apr 14.